PT-141 (bremelanotide) is the only peptide on this list that's actually FDA-approved. Marketed as Vyleesi, it cleared FDA review in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. That makes it a real prescription drug with Phase III data behind it, not a grey-market research compound. Which changes everything about how you buy it, what quality you get, and what your prescriber should be telling you (FDA, Vyleesi label, 2019).
The catch: Vyleesi's approval is narrow. Premenopausal women, HSDD only. Not men. Not situational use. Not performance enhancement. Off-label prescribing for men is legal but doesn't have the FDA-reviewed efficacy backing. Which lane you're in determines which access route fits.
Key Takeaways
- —PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women — a real prescription drug, not a research compound. Qualifying patients pay $0 for a 4-dose starter box via Palatin's patient program.
- —The mechanism is central: MC4R (melanocortin-4 receptor) activation in the brain. Completely different from PDE5 inhibitors (sildenafil, tadalafil), which work peripherally on blood flow.
- —Off-label prescribing for men is legal under physician discretion. No FDA-reviewed RCT supports this use, but there's Phase II data.
- —Research-grade PT-141 from unregulated vendors has no quality oversight. The FDA-approved route is accessible and often free or low-cost for women with HSDD.
PT-141 is a cyclic heptapeptide, MW 1025.18 Da, derived from Melanotan II. Chemical name: bremelanotide. What separates it from every other sexual dysfunction drug is where it acts. Not in the genitals. In the brain. Specifically the hypothalamus, via melanocortin-4 receptor (MC4R) activation.
Sildenafil (Viagra), tadalafil (Cialis), and the rest of the PDE5 inhibitors are peripheral. They block phosphodiesterase-5, which relaxes smooth muscle and pushes more blood into genital tissue. They need sexual stimulation to do anything. PT-141 doesn't touch blood flow directly. It modulates dopaminergic pathways centrally to crank up sexual desire — the motivation side, not the vascular side. Which is why it landed first in women, where desire disorder is usually the primary complaint, and why the felt experience is different from PDE5 in both sexes.
The side effect profile is worth surfacing before you buy anything. Nausea is the most commonly reported, followed by flushing and a transient bump in blood pressure. None of that means your product is bunk. It means it's working. If you've got uncontrolled hypertension or cardiovascular issues, this is the wrong compound, full stop.
Three distinct lanes, three different quality and cost stories.
1. FDA-approved Vyleesi (premenopausal women with HSDD). The only lane with full pharma-grade quality assurance. GMP manufacturing, dispensed via licensed pharmacies, Phase III trial data behind it. Palatin Technologies (the manufacturer) runs a patient assistance program: commercially insured patients who meet the HSDD criteria pay $0 for the first 4-dose box. Subsequent boxes drop to reduced pricing through the savings programme. This isn't widely advertised, so plenty of eligible patients are paying full freight when they don't have to.
2. Tele-doc prescription, off-label (men, postmenopausal women). PT-141 isn't approved for men or for women past menopause, but off-label prescribing under physician judgement is legal. Several telehealth platforms will write bremelanotide for men with ED who didn't respond to PDE5 inhibitors, or for whom PDE5 is contraindicated. What gets dispensed is either brand-name Vyleesi or compounded bremelanotide from a 503A pharmacy, depending on shortage status. Both require a valid Rx. This is the practical lane for most people who aren't women with HSDD.
3. Research-grade vials from unregulated vendors. The grey-market route. No prescription, no physician oversight, no pharmaceutical QC. Sits in the same regulatory zone as other unscheduled research peptides. Quality verification is on you: HPLC, mass spec, COA, batch traceability. MW 1025.18 Da is your MS confirmation target. Cheaper than Vyleesi by a wide margin, but you're trading price for the absence of oversight.
For women with HSDD, the data is solid enough that the FDA approved it. The Phase III RECONNECT trial showed statistically significant gains in the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Desire (FSDS-DAO) versus placebo over 24 weeks. Mean increase in satisfying sexual events was the primary endpoint. The drug cleared it.
For men, the evidence is thinner. There's Phase II data showing bremelanotide improved erectile function scores in men with ED, including those who hadn't responded to sildenafil. But no Phase III RCT in men has been published. The off-label male use is built on that Phase II signal plus the mechanistic logic that MC4R isn't sex-specific at the receptor level. From what people report on the men's side, it works, but the evidence base is what it is.
The full PT-141 research profile on Next Pep walks through the complete MC4R mechanism, the RECONNECT data, the PDE5 comparison, and the Phase II male data without sugar-coating. Read that before you talk to any prescriber or vendor.
If you're going research peptide, not the path most use cases need, the standard verification stack applies:
HPLC purity ≥98%. Research-grade minimum. Anything below that is bunk. MS at 1025.18 Da. Confirms it's actually bremelanotide. Third-party tested COA with verifiable lot number. Standard across all research peptides. The report ID has to resolve on the issuing lab's server. If it doesn't, the COA is decorative. Lyo powder. PT-141 degrades in solution. White or off-white powder only. If it ships pre-mixed, walk away.
One more flag worth knowing. PT-141 reconstitutes in BAC water to 10 mg/mL, and the clinical dose used in RECONNECT was 1.75 mg. Vendors pushing doses well above 2 mg are recommending more than the Phase III protocol tested. That's worth weighing when you're looking at their marketing copy. Bigger isn't better here. The side effect curve is steep.
The detailed PT-141 research guide covers the MC4R mechanism, the RECONNECT trial data, the PDE5 comparison, and the Phase II male evidence so you walk into a prescriber or vendor conversation knowing what's real. The peptide library gives you PT-141's full molecular profile — MW 1025.18 Da, sequence, pharmacokinetics, regulatory summary — in one cross-referenced view.
If you're comparing PT-141 against other compounds for the same use, the comparison tool puts mechanisms side by side without the vendor spin. For any injectable protocol, the dosing calculator handles the reco math: punch in your vial concentration (typically 10 mg/mL) and target dose, get exact draw volume and syringe units. Next Pep is the neutral starting point. Use it before you talk to anyone selling something.
Yes. Vyleesi is the brand name for bremelanotide (PT-141), the FDA-approved subq injection for HSDD in premenopausal women. The peptide sequence is identical. What's different is everything around it: Vyleesi is GMP-manufactured, dispensed through licensed pharmacies with a prescription, and backed by Phase III trial data. Research-grade PT-141 from unregulated vendors has none of those guarantees.
Qualifying premenopausal women with HSDD who are commercially insured can get their first 4-dose box of Vyleesi at $0 through Palatin's patient savings programme. Boxes after that drop to reduced cost. Without insurance, Vyleesi list price varies by pharmacy. Off-label compounded bremelanotide through a tele-doc platform is typically $100–200 per course. Research-grade PT-141 ranges all over. Price alone tells you nothing about quality.
PT-141 isn't FDA-approved for men. A licensed physician can still prescribe it off-label at their discretion — that's legal under the Federal Food, Drug, and Cosmetic Act. The prescriber takes on the responsibility for the call. The evidence supporting male use is Phase II only, not Phase III, which means the evidence base is weaker than for the approved female HSDD indication. Most men accessing PT-141 legally do it through telehealth.
The FDA-approved dose of Vyleesi is 1.75 mg subq, taken roughly 45 minutes before anticipated sexual activity. No more than one dose per 24 hours, no more than one per week. RECONNECT used this dose. Doses you'll see in research vendor protocols sometimes run higher. Anything significantly above 1.75 mg is outside the tested clinical range, and the side effect profile (nausea, flushing, BP elevation) gets worse at higher doses.
This article is for informational purposes only. Vyleesi (bremelanotide) is an FDA-approved prescription medication for HSDD in premenopausal women. Off-label use requires a licensed physician's prescription. PT-141 from research vendors has no regulatory quality oversight. Consult a qualified healthcare professional.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.